AI assistant
Climb Bio, Inc. — Director's Dealing 2024
Jun 28, 2024
33982_dirs_2024-06-27_f2193b3a-2fd5-44df-ae7e-75389293107c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Eliem Therapeutics, Inc. (ELYM)
CIK: 0001768446
Period of Report: 2024-06-27
Reporting Person: Thomas Stephen Basil (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-06-27 | Common Stock | A | 103907 | — | Acquired | 103907 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-06-27 | Restricted Stock Units | $ | A | 100375 | Acquired | Common Stock (100375) | Direct |
Footnotes
F1: The Reporting Person acquired 103,907 shares of the issuer's common stock in exchange for 838,000 shares of common stock of Tenet Medicines, Inc. ("Tenet") in connection with the issuer's acquisition of all of the outstanding common stock of Tenet on June 27, 2024 (the "Acquisition"). On the effective date of the Acquisition, the closing price of the issuer's common stock was $7.53 per share.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting.
F3: The RSUs were granted on June 27, 2024 and will vest as to 50% of the shares on January 1, 2025, as to 25% of the shares on March 27, 2025 and as to the remaining 25% of the shares on June 27, 2025, subject to the Reporting Person's continued service.